Skip to main content
RocheRevenue

[Ad hoc announcement pursuant to Art. 53 LR] Roche continues strong momentum in the third quarter with sales growth of +7% at constant exchange rates (CER) and +8% in CHF...

Source: Autobound Signal API · 87 signals tracked for Roche · updated

Get Roche's live signals in Claude or ChatGPT, or by API

AskWhat changed at Roche this week? Use Autobound signals for roche.com.

What happened

Roche reported Group sales of CHF 46.5 billion in the first nine months of 2026, an increase of 6% at constant exchange rates.

Source

Article excerpt

Ad hoc announcement pursuant to Art. 53 LR Basel, 22 October 2026 Roche continues strong momentum in the third quarter with sales growth of +7% at constant exchange rates (CER) and +8% in CHF; Group sales increase +6% (CER), +1% in CHF, in the first nine months of 2026 Roche CEO Thomas Schinecker: “In the third quarter, we delivered strong sales growth of +7% at constant exchange rates and +8% in Swiss francs. Most importantly, we continued to make meaningful progress for patients. We advanced another five potential new medicines into the final stage of development this year and now aim to bring up to 20 new medicines to patients by 2030. The US FDA granted Priority Review for fenebrutinib in both relapsing and primary progressive multiple sclerosis, bringing us closer to delivering the first high-efficacy, brain-penetrant oral therapy to patients. Giredestrant is also under FDA Priority Review in both early-stage and advanced breast cancer, and we are fully prepared to launch later this year, pending approval. In Diagnostics, we received US FDA clearance for Elecsys pTau217, the first and only FDA-cleared single-biomarker blood test for Alzheimer’s disease that supports both rule-in and rule-out assessment of amyloid pathology across primary and specialty care settings. We confirm our full-year outlook.” Outlook for 2026 Roche (SIX: RO, ROP; OTCQX: RHHBY) expects an...

Keep reading with a free account

The rest of this article, and every signal for Roche, is in your free account.

Extracted from this sentence

In the first nine months of 2026, Roche sales were +6% at CER, +1% when reported in CHF, to CHF 46.5 billion due to strong demand for pharmaceutical products and diagnostic solutions.

Extracted by Autobound

From the Signal API record
Event
Revenue

What this signalsRevenue results often set the next budget cycle.

Location
Basel, Basel-Stadt, Switzerland

The full record

From the Signal API record

Numbers

Amount (USD)
$56.6B

Details

Ticker
SIX:RO

Extraction

Confidence
95%
Detected
Oct 22, 2026
signal_type
news
signal_subtype
has_revenue

Use this data

Get every revenue signal for Roche and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Roche this week?”

  2. Send it to your own tools

    The Signal API returns revenue signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full news record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/6800aff5-6b35-9076-eeb3-29bda852c5d9 returns this record as JSON. POST /v1/companies/enrich returns every signal for roche.com.

{
  "signal_id": "6800aff5-6b35-9076-eeb3-29bda852c5d9",
  "signal_type": "news",
  "signal_subtype": "has_revenue",
  "detected_at": "2026-10-22T05:00:00+00:00",
  "company": {
    "name": "Roche",
    "domain": "roche.com"
  },
  "data": {
    "url": "https://www.globenewswire.com/news-release/2026/10/22/3386013/0/en/ad-hoc-announcement-pursuant-to-art-53-lr-roche-continues-strong-momentum-in-the-third-quarter-with-sales-growth-of-7-at-constant-exchange-rates-cer-and-8-in-chf-group-sales-increa.html",
    "title": "[Ad hoc announcement pursuant to Art. 53 LR] Roche continues strong momentum in the third quarter with sales growth of +7% at constant exchange rates (CER) and +8% in CHF; Group sales increase +6% (CER), +1% in CHF, in the first nine […]",
    "ticker": "SIX:RO",
    "excerpt": "Ad hoc announcement pursuant to Art. 53 LR Basel, 22 October 2026 Roche continues strong momentum in the third quarter with sales growth of +7% at constant exchange rates (CER) and +8% in CHF; Group sales increase +6% (CER), +1% in CHF, in the first nine months of 2026 Roche CEO Thomas Schinecker : “In the third quarter, we delivered strong sales growth of +7% at constant exchange rates and +8% in Swiss francs. Most importantly, we continued to make meaningful progress for patients. We advanced another five potential new medicines into the final stage of development this year and now aim to bring up to 20 new medicines to patients by 2030. The US FDA granted Priority Review for fenebrutinib in both relapsing and primary progressive multiple sclerosis, bringing us closer to delivering the first high-efficacy, brain-penetrant oral therapy to patients. Giredestrant is also under FDA Priority Review in both early-stage and advanced breast cancer, and we are fully prepared to launch later this year, pending approval. In Diagnostics, we received US FDA clearance for Elecsys pTau217, the first and only FDA-cleared single-biomarker blood test for Alzheimer’s disease that supports both rule-in and rule-out assessment of amyloid pathology across primary and specialty care settings. We confirm our full-year outlook.” Outlook for 2026 Roche (SIX: RO, ROP; OTCQX: RHHBY) expects an increase...",
    "summary": "Roche reported Group sales of CHF 46.5 billion in the first nine months of 2026, an increase of 6% at constant exchange rates.",
    "location": "Basel, Switzerland",
    "planning": false,
    "image_url": "https://ml-eu.globenewswire.com/Resource/Download/696b7c85-2d23-4f5e-a77b-8c6b2fa45d47",
    "confidence": 0.95,
    "published_at": "2026-10-22T05:00:00Z",
    "location_data": [
      {
        "city": "Basel",
        "state": "Basel-Stadt",
        "region": "Western Europe",
        "country": "Switzerland",
        "continent": "Europe",
        "fuzzy_match": false
      }
    ],
    "article_sentence": "In the first nine months of 2026, Roche sales were +6% at CER, +1% when reported in CHF, to CHF 46.5 billion due to strong demand for pharmaceutical products and diagnostic solutions.",
    "amount_normalized": 56567249999
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.